林礼务,林学英,薛恩生,何以敉,高上达,林晓东,吴丽足.超声介入无水乙醇量化治疗合并肝硬化的复发性肝癌的临床研究[J].中国医学影像技术,2006,22(1):117~120
超声介入无水乙醇量化治疗合并肝硬化的复发性肝癌的临床研究
Percutaneous quantif ied ethanol injection in the treatment for recurrent hepatocellular carcinoma with intercurrent hepatocirrhosis
投稿时间:2005-09-08  修订日期:2005-11-06
DOI:
中文关键词:  癌,肝细胞  肝硬化  超声介入  无水乙醇  量化治疗
英文关键词:Carcinoma, hepatocellular  Hepatocirrhosis  Interventional ultrasound  Anhydrous ethanol  Quantified therapy
基金项目:
作者单位E-mail
林礼务 福建医科大学附属协和医院超声科,福建省超声医学研究所,福建福州 350001 lxyycb@sina.Com 
林学英 福建医科大学附属协和医院超声科,福建省超声医学研究所,福建福州 350001  
薛恩生 福建医科大学附属协和医院超声科,福建省超声医学研究所,福建福州 350001  
何以敉 福建医科大学附属协和医院超声科,福建省超声医学研究所,福建福州 350001  
高上达 福建医科大学附属协和医院超声科,福建省超声医学研究所,福建福州 350001  
林晓东 福建医科大学附属协和医院超声科,福建省超声医学研究所,福建福州 350001  
吴丽足 福建医科大学附属协和医院超声科,福建省超声医学研究所,福建福州 350001  
摘要点击次数: 1970
全文下载次数: 60
中文摘要:
      目的 评价超声介入注射无水乙醇量化( PQEI) 治疗合并肝硬化复发性肝癌的临床应用价值及其相关技术。方法 临床病理证实的合并肝硬化复发性肝癌298 例。行超声介入无水乙醇量化注射治疗,注射量按回归方程Y=2 885X(当肿瘤直径≤5 cm 时) ,Y= 1. 805X (当肿瘤直径> 5 cm时) 计算(X 为肿瘤最大直径,单位为cm; Y为注射乙醇量,单位为ml) ,每周注射2~3 次,≤5cm的肿瘤结节4~10 次为一疗程, > 5 cm 肿瘤结节以10~20 次为一疗程。病例随访12~60 个月。观察临床症状与体征,并结合相关检查结果。统计1 、2 、3 、4 、5 年生存率。结果 超声引导无水乙醇量化注射治疗后肿瘤平均直径从3. 4 cm 降为2. 8 cm。治疗后1 、2 、3 、4 、5 年生存率分别为89. 7 %、78. 8 %、66. 3 %、56. 5 % 和46. 7 % ,中位数生存期为44.2 个月。298 例HCC 先后进行2871 次PQEI ,除短期内出现疼痛、低烧、轻度黄疸等,均无大出血和严重心、肾功能损害等并发症发生,其中4 例因合并严重的肝硬化肝功能衰竭而死。结论 超声介入无水乙醇量化治疗合并肝硬化复发性肝癌有较高的临床应用价值,值得深入研究。
英文摘要:
      Objective To evaluate the clinical application value of percutaneous quantified ethanol injection ( PQEI) in the t reatment for recurrent hepatocellular carcinoma ( HCC) with intercurrent hepatocirrhosis. Methods The tumors in 298 ca-ses of clinicopathologically proven HCC were injected with quantified ethanol guided by ult rasound every 2 - 3 days. The quantity of ethanol was calculated according to the regressive equations which were Y= 2. 885X when the mass wa s ≤5 cm in diameter and Y= 1. 805X when the mass was > 5 cm in diameter (X was the maximal diameter of the mass with the unit cm , Y was the ethanol quantity with the unit ml) . The ethanol was injected for 4 - 10 times per period for tumors ≤5 cm in di-ameter and 10 - 20 times per period for tumors > 5 cm in diameter. The follow2up period lasted 12 - 60 months. The thera-peutic efficacy was assessed by clinical symptom , the result of US , CT , MRI , color three2dimensional ult rasound and biop-sy. The survival rates of 1 ,2 ,3 ,4 ,5 years were calculated. Results All the 387 nodules in 298 cases of HCC shrank f rom3. 4 cm to 2. 8 cm in average diameter af ter 2 - 8 weeks since the last PEI. The survival rates of 1 ,2 ,3 ,4 ,5 years were89.7%,78.8%,66.3%,56.5 % and 46.7% , respectively. The median survival time was 44. 2 months. The 298 cases un-derwent 2871 PQEI in total. There were no complications such as hemorrhage and severe heart and kidney damage except different degree of pain,low-fever, jaundice in short period of time. Four cases died companion of serious hepatocirrhosis which resulted in liver function failure. Conclusion PQEI is of high clinical pplication value for the t reatment of recurrent hepatocellular carcinoma and deserves further research.
查看全文  查看/发表评论  下载PDF阅读器